Next, we transplanted the iPS cells secreting mNAGA into the testes of Fabry disease model mice. After 7 or 8 weeks, the GLA activity in the liver was significantly improved, although no recovery ...

"ALA-CART improves the ability of CAR-T cells to detect and attack resistant cancer cells more effectively. This could lead to longer lasting results, even when other treatments have failed," said ...

IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treatment of Cardiomyopathy Associated with Danon disease Marks third Rare Pediatric Drug Designation ...

Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the ...

Months after announcing an M&A deal with AstraZeneca, EsoBiotec has released the first small slice of data on the cell ...

Emiri Nakamura and Professor Koji Eto (Department of Clinical Application) has identified microtubule (MT) destabilization as ...

Promising CART T cancer therapy invented at Penn linked to rare, secondary cancers, FDA says . The agency said it received 19 reports of new blood cancers in patients who got the CAR T treatment.

One such successful case is that of Rajeev, a 68-year-old retired railway officer from Mysore, who was able to be successfully treated through CART-Cell Therapy at Cytecare Hospitals, the Cancer ...

HOUSTON--(BUSINESS WIRE)--IPS HEART has been granted rare pediatric drug designation by the FDA for GIVI-MPC, a first-in-class stem cell therapeutic to create new skeletal muscle with 100% full ...

The first CAR-T therapy — which was manufactured by Novartis — was approved by the FDA in 2017 for the treatment of pediatric and young adult patients with B-cell acute lymphoblastic leukemia. "I have ...